Please select the option that best describes you:
Would you consider TPO agonists for thrombocytopenia from low risk MDS?
What do you think about the long term risk of AML with romiplostim with longer follow up studies? What about using other TPO agonists like eltrombopag or avatrombopag?
Answer from: at Academic Institution
There are randomized data supporting the use of TPO agonists in low-risk MDS with thrombocytopenia. A phase II study of eltrombopag vs placebo demonstrated a platelet response in ~40% of patients treated with eltrombopag and no increased risk of disease progression/AML evolution between the eltrombo...
Sign in or Register to read more